Significance Statement: Sensory nerve fibers sprouting in bone pathologies is highly associated with pain.
The raw data was processed using the Proteome Discoverer software (Thermo Scientific) and compared 
197
Network analysis was performed using the Cytoscape software (version v3.7.1) (Cytoscape Consortium,
198
San Diego, CA, US)) with the plugins ClueGO (version v2.5.4) and CluePedia (version v1.5.4). We used 199 ClueGO's default settings: merge redundant groups with >50.0% overlap; the minimum GO level used was 200 0 and the maximum GO level was 2; statistical test used was "Enrichment/Depletion (Two-sided 201 hypergeometric test)", Bonferroni step down p-value correction; Kappa Score Threshold was 0.5; and 202 number of genes was set at 3 with a minimum percentage at 4.0.
203

Analysis of Phospho-Receptor Tyrosine Kinase (RTK) activation
204
A proteome profiler mouse phospho-RTK array kit (#ARY014, R&D system, Minneapolis, MN, USA) was 205 used to quantify the phosphorylation level of 39 RTKs. After 72 h of treatment with conditioned medium 206 and controls, protein lysate of DRG was quantified and analyzed. The protein content (from 6-10 DRG) of 207 the same condition, from each independent experiment, was pooled together. According to the 208 manufacturer's instructions, for the array analysis, the same amount of protein was added to each 209 membrane. Each array membrane was exposed to X-ray film using a chemiluminescence detection system 210 (Amersham, GE Healthcare). The film was scanned using Molecular Imager GS800 calibrated densitometer 211 (Bio-Rad, Hercules, CA, USA) and pixel density was quantified using Quantity One 1-D Analysis 212 Software, v 4.6 (Bio-Rad). The results were presented as the mean spot intensity which corresponds to the 213 mean of the two spots for each receptor within the same membrane array.
214
Pharmacological inhibition of epidermal growth factor receptor (EGFR) and ErbB2 
219
Trastuzumab was tested in DRG cultures at a concentration of 10 µg/mL in conditioned medium.
220
Afterward, axonal outgrowth was measured as previously described.
221
1 integrin subunit function blocking
222
To assess the contribution of the β1 integrin subunit on the phosphorylation of EGFR and osteoclast- 
231
Extracellular vesicles (EV) depletion from the osteoclast secretome and characterization
232
Osteoclasts were isolated and differentiated as described in previous sections. After seeding on 48 well 233 plates, cells were cultured with 10% EV-depleted FBS. 24h prior media collection, FBS was reduced to 234 1%. All steps for the EV depletion were conducted under sterile conditions and in line with the published
235
Minimal information for studies of extracellular vesicles 2018 guidelines (Théry et al., 2018) and as 236 described in (Théry et al., 2006) . Briefly, the secretome was collected, centrifuged 1 000g 10 min to clear 237 the cell debris, 2 000g for 10 min, followed by 10 000g for 30 min. The supernatant was then centrifuged 238 at 100 000g using 70Ti rotor (Beckman Coulter Genomics), for 120 min. The pellet containing exosomes 239 was then resuspended in PBS and stored at -80C. All centrifugation steps were performed at 4C (Tassew 
242
Western blot (WB) analysis was performed to the protein content from the EV enriched fraction. Protein 243 was quantified by DC Protein Assay kit (Bio-Rad). The same amount of protein (15 μg) of the EV enriched 244 10 of 37 fraction and the corresponding supernatant were prepared in non-reducing loading buffer, denatured at 95°C 245 for 5 min, and loaded in 10% polyacrylamide SDS-PAGE gels. Resolved proteins were wet-transferred to 246 nitrocellulose membranes, and membranes blocked with non-fat dry milk 5% solution. Membranes were 247 probed overnight at 4°C with hamster anti-mouse CD81 antibody, clone Eat2 (MCA1846GA, Bio-Rad).
248
Membranes were probed with HRP-conjugated secondary antibody (GE Healthcare), incubated with ECL 249 substrate, and chemiluminescence signal was detected with autoradiographic films (all from GE 250 Healthcare). Films were scanned on a GS-800 calibrated imaging densitometer (Bio-Rad).
251
The osteoclast-derived EV enriched fraction was further characterized by nanoparticle tracking analysis 
253
Briefly, for size and particle concentration evaluation, EV suspensions were diluted 1:500 in filtered PBS monitored. After mounting, µEFs were sequentially coated with poly-D-lysine (PDL) (0.01 mg/ml)
274
(Corning) and laminin (0.01 mg/ml) (Sigma-Aldrich). The unbound laminin was aspirated, and chambers 275 were refilled with complete neurobasal medium and left to equilibrate at 37 °C. Isolated embryonic DRG 276 explants were placed and cultured as described before. DRG explants extended axons to the axonal 277 compartment within the first 5 days in vitro (DIV). Then, treatments and recordings were performed at 6-7 278 DIV. This time point was chosen following preliminary studies that showed adequate electrophysiological 279 maturation and culture viability at this stage (Heiney et al., 2019).
280
Besides the positive control composed of complete neurobasal supplemented with NGF, three conditions 281 with osteoclast secretome were tested. The total mature osteoclast secretome, the EV-depleted osteoclast 282 secretome and secretome from osteoclasts cultured in mineralized substrates.
283
Recordings at a sampling rate of 20 kHz were performed using a MEA2100 recording system (MCS GmbH,
284
Germany). In every recording session, the temperature was maintained at 37ºC by an external temperature 285 controller. After removing the cultures from the incubator, recordings only started after 5 minutes of 286 habituation to avoid an effect due to mechanical perturbation. Then, a baseline recording (5 minutes) was 287 obtained. Afterward, the medium from the axonal compartment was gently aspirated and replaced by 100 288 μl of treatment medium. The larger volume present on the somal compartment maintained a hydrodynamic 289 pressure difference, inhibiting any flow from the axonal to the somal compartment.
290
Post-treatment (timepoint 0h) recordings (20-30 minutes) were started as soon as the baseline stabilized 291 following liquid flow perturbation (less than 1 minute). Cultures were returned to the incubator until 3 hours 292 after treatment, when a post-treatment recording (timepoint 3h) of 5-10 minutes was performed. The day 293 after, a final post-treatment recording (timepoint 24h) was performed for 5-10 minutes.
294
Raw signals were high-pass filtered (200 Hz) and spikes were detected by a threshold set to 5× SD of the 295 electrode noise. Spike data analysis was carried out in MATLAB R2018a (The MathWorks Inc., USA) 296 using custom scripts. The mean firing rate (MFR) of each microchannel was calculated by averaging the 297 MFR of the 5 inner electrodes (typically electrode rows 10-14), due to their superior signal-to-noise ratio.
298
Microchannels with an MFR of at least 0.1 Hz in a given time point at 6 DIV were considered as active and between groups were calculated using one-way analysis of variance, more precisely, the non-parametric 304 Kruskal-Wallis test followed by Dunns post test for multiple comparisons. The non-parametric Mann-
305
Whitney t-test was used to identify statistical differences when only two groups where being compared.
306
Differences between groups were considered statistically significant when *0.01 < p < 0.05, ** 0.001 < p 307 < 0.01, *** p < 0.001, **** p < 0.0001. 308 13 of 37
Results
309
Sensory neurons outgrowth under osteoclasts effect is neurotrophin-independent 310
To understand the response of peripheral sensory nerves to the cells present in the bone compartment we 311 assessed the effect of the secretome from osteoclasts lineage, at different stages of differentiation, in axonal 312 growth and sprouting of dorsal root ganglia (DRG). We compared these effects with the neurotrophic effect 313 of bone marrow stromal cells (BMSC).
314
Organotypic explants of embryonic DRG cultures were exposed to the secretome derived from BMSC, 
336
Representative images of DRG outgrowth after treatment (stained for III-tubulin, scale bar 500 µm).
337
Neurobasal supplemented with nerve growth factor (NB); bone marrow stromal cells conditioned medium 
404
An antibody-based 1 integrin subunit blocker and the respective isotype were added to the osteoclast 405 secretome, and axonal sprouting was measured. No differences in the axonal outgrowth was observed when 406 the anti-1 integrin isotype was added to the osteoclast secretome (supplemental Figure S3 ). Regarding the 407 functional blocker, the treatment induced a significant decrease in the axonal outgrowth area when 408 compared to the control (Figure 4A-B) . Nevertheless, no alterations of EGFR family phosphorylation were 409 observed when the activity of 1 integrin was reduced ( Figure 4C ). These results were further supported 410 by immunocytochemistry where phosphorylated EGFR was detected independently on the condition 411 analyzed ( Figure 4D ). 
432
Over four hundred proteins were identified in the osteoclast serum-free secretome. The complete set of 433 identified proteins is available as supplemental data (supplemental Table S1 ). Protein identification 434 revealed oscillations in the relative concentration of the soluble factors throughout the conditioning period.
435
As expected, the higher amount of the identified proteins at 24 h were increased in relative concentration 436 when compared to 6 h.
437
Interestingly, the identified proteins were not only assigned to the extracellular region (extracellular matrix Figure 5A ). By restricting the analysis to pathways with a higher significance 442 (p<0.01) and increasing the specificity level of the cellular component terms, we observed that the majority 443 of the proteins remained associated to the initial detected clusters ( Figure 5B and supplemental table S2 ).
444
Importantly, neither EGF nor TGF were identified among the secreted proteins, which is in accordance 445 with a previous study reporting briefly the analysis of the osteoclast secretome where no EGFR ligands Neurotrophic proteins, are generally believed to be released from cells in a soluble form and act locally or 468 move through the extracellular milieu, which lead us to perform the proteomic profiling in the total 469 secretome. However, it is increasingly appreciated that growth factors can be released from cells in or on 470 the surface of extracellular vesicles (EV)/exosomes (Jaiswal and Sedger, 2019). We, therefore, 471 hypothesized that osteoclast-derived EV could play a crucial role in the axonal outgrowth. To test this, 472 DRG were exposed to EV-depleted osteoclast secretome and the axonal sprouting was measured. The EV 473 enriched fraction was characterized by NTA, WB and by TEM. The analysis of the size and concentration 474 of the vesicles showed a normal distribution with a mean size of 141.8 ± 2.7 nm and a concentration of 4.90 475
x 10 11 particles/ml (supplemental Figure S4 ). The analyzed fraction stained positive for the CD81 EV-476 specific marker ( Figure 6A ) and by negative staining for TEM, it was possible to visualize the EV present 477 in the OC-derived secretome ( Figure 6B , white arrowheads), ranging from 40 to 200 nm.
478
A significant decrease in axonal sprouting was observed in the absence of EV ( Figure 6C-D) . This suggests 479 that the EV cargo plays a role in the neurotrophic potential of the osteoclast secretome. To understand if 480 EV depletion modulates the EGFR/ErbB2 phosphorylation levels, that we previously demonstrated to be 481 involved in the osteoclast-induced axonal outgrowth, we evaluated the phosphorylation state of the EGFR 482 family. Remarkably, a substantial decrease in EGFR family phosphorylation was observed in the absence 483 of osteoclast-derived EV ( Figure 6E) , confirming that the EGFR family activator is present in the EV cargo 484 and reinforcing the contribution of this signaling pathway to the osteoclast-mediated axonal growth.
485
Therefore, the EV enriched fraction was further analyzed by LC-MS/MS for the identification of potential 
